Upregulation of MiR-2861 and MiR-451 Expression in Papillary Thyroid Carcinoma with Lymph Node Metastasis

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2013 Apr 24

PMID 23609190

Citations 42

Authors

Zhihong Wang

Hao Zhang

Ping Zhang

Jing Li

Zhongyan Shan

Weiping Teng

Affiliations

Soon will be listed here.

Abstract

MicroRNA (miRNA) expression is deregulated in many types of human cancers, including thyroid cancer. The purpose of this study was to investigate miRNA deregulation in papillary thyroid carcinoma (PTC), particularly with lymph node (LN) metastasis. To identify the miRNA signature in PTC with LN metastasis, miRNAs isolated from PTC patients with LN metastasis (n = 3) and without LN (NLN) metastasis (n = 3) were used for microarray analysis. Four differentially expressed miRNAs including miR-2861, miR-451, miR-193b, and miR-1202 were selected for further validation between the LN group (n = 51) and the NLN group (n = 36) using real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The miRNA microarray results showed that compared to the NLN group, upregulation of four miRNAs including miR-2861, miR-451, miR-193b, and miR-1202 was associated with LN metastasis, whereas four other miRNAs including miR-let-7i, miR-542-5p, miR-664*, and miR-564 were downregulated in the LN group. In the validation cohort, the expression of either miR-2861 or miR-451 in the LN group was significantly greater than that in the NLN group (P = 0.004 and 0.026, respectively). Furthermore, the expression levels of miR-2861 and miR-451 in lateral lymph node (LLN) metastasis were significantly greater than those in central lymph node (CLN) metastasis (P = 0.007 and 0.001, respectively). Upregulated expression of miR-2861 and miR-451 in PTC with LN metastasis represents a unique miRNA signature associated with the prognosis and progression of PTC.

Citing Articles

Bioinformatics analysis of miR-2861 and miR-5011-5p that function as potential tumor suppressors in colorectal carcinogenesis.

Aytekin A, Kadakal H, Mihcioglu D, Gurer T BMC Med Genomics. 2025; 18(1):1.

PMID: 39748239 PMC: 11697744. DOI: 10.1186/s12920-024-02080-6.

Higher microRNA-221 and lower microRNA-451 expression are associated with poor prognosis in patients with thyroid papillary carcinoma.

Wu J, Sun W, Shen J, Hu L An Sist Sanit Navar. 2024; 47(2).

PMID: 39177218 PMC: 11410297. DOI: 10.23938/ASSN.1086.

Supragingival Bacterium Oral Infection-Induced Periodontitis and Robust miRNA Expression Kinetics.

Aravindraja C, Jeepipalli S, Duncan W, Vekariya K, Rahaman S, Chan E Int J Mol Sci. 2024; 25(11).

PMID: 38892405 PMC: 11172800. DOI: 10.3390/ijms25116217.

miR-1202 regulates BPH-1 cell proliferation, apoptosis, and epithelial-to-mesenchymal transition through targeting HMGCL.

Wang Z, Yin X, Yang P, Gong B, Liu H Acta Biochim Biophys Sin (Shanghai). 2024; 56(5):675-687.

PMID: 38551020 PMC: 11177111. DOI: 10.3724/abbs.2024001.

Involvement of FAM170B-AS1, hsa-miR-1202, and hsa-miR-146a-5p in breast cancer.

Abd ELhafeez A, Ghanem H, Swellam M, Taha A Cancer Biomark. 2024; 39(4):313-333.

PMID: 38250762 PMC: 11091646. DOI: 10.3233/CBM-230396.

References

Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y . MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 2010; 1359:14-21. DOI: 10.1016/j.brainres.2010.08.074. View

Chou C, Yang K, Chou F, Huang C, Lan Y, Lee Y . Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012; 98(2):E196-205. DOI: 10.1210/jc.2012-2666. View

Xing M . BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28(7):742-62. DOI: 10.1210/er.2007-0007. View

Gimm O, RATH F, Dralle H . Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg. 1998; 85(2):252-4. DOI: 10.1046/j.1365-2168.1998.00510.x. View

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Lim Y, Lee J, Lee Y, Lee B, Wang S, Son S . Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery. 2011; 150(1):116-21. DOI: 10.1016/j.surg.2011.02.003. View

Yip L, Kelly L, Shuai Y, Armstrong M, Nikiforov Y, Carty S . MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011; 18(7):2035-41. PMC: 4157306. DOI: 10.1245/s10434-011-1733-0. View

Kitano M, Rahbari R, Patterson E, Steinberg S, Prasad N, Wang Y . Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid. 2012; 22(3):285-91. PMC: 3286806. DOI: 10.1089/thy.2011.0313. View

10.

Jiang J, Lee E, Gusev Y, Schmittgen T . Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005; 33(17):5394-403. PMC: 1236977. DOI: 10.1093/nar/gki863. View

11.

Brenner B, Hoshen M, Purim O, David M, Ashkenazi K, Marshak G . MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol. 2011; 17(35):3976-85. PMC: 3199555. DOI: 10.3748/wjg.v17.i35.3976. View

12.

Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H . Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 2012; 106(4):740-7. PMC: 3322946. DOI: 10.1038/bjc.2011.588. View

13.

Calin G, Liu C, Sevignani C, Ferracin M, Felli N, Dumitru C . MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004; 101(32):11755-60. PMC: 511048. DOI: 10.1073/pnas.0404432101. View

14.

Fabbri M, Ivan M, Cimmino A, Negrini M, Calin G . Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther. 2007; 7(7):1009-19. DOI: 10.1517/14712598.7.7.1009. View

15.

Chou C, Chen R, Chou F, Chang H, Chen Y, Lee Y . miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid. 2010; 20(5):489-94. DOI: 10.1089/thy.2009.0027. View

16.

Sand M, Skrygan M, Sand D, Georgas D, Hahn S, Gambichler T . Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 2012; 167(4):847-55. DOI: 10.1111/j.1365-2133.2012.11022.x. View

17.

Shen R, Liyanarachchi S, Li W, Wakely Jr P, Saji M, Huang J . MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases. Thyroid. 2011; 22(1):9-16. PMC: 3247703. DOI: 10.1089/thy.2011.0081. View

18.

Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F . Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007; 31(11):2085-91. DOI: 10.1007/s00268-007-9224-y. View

19.

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

20.

Zhou Y, Liu C, Dai X, Zhang X, Wang O . Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas. Med Oncol. 2012; 29(5):3360-6. DOI: 10.1007/s12032-012-0315-8. View